论文部分内容阅读
成本效益[Cost-Benefit(CB)]是评价卫生防疫工作效果的重要指标。免疫预防又是控制和消除相应传染病的有效手段。近年来,Hinman等对于计划免疫的成本效益进行了探讨。在麻疹计划免疫工作中,CB是以接种麻疹疫苗(MV)的成本费用(包括购置MV及其管理费用等)为分子,以效益(即免疫后少发生病例的治疗费用等)为分母的金钱比例关系。
Cost-Benefit (CB)] is an important indicator to evaluate the effect of health and epidemic prevention. Immunoprophylaxis is an effective measure to control and eliminate the corresponding infectious diseases. In recent years, Hinman et al explored the cost-effectiveness of planned immunization. In the measles immunization program, CB is based on the cost of immunization against measles (MV), including the purchase of MVs and their administrative expenses, and the denominator of benefits (ie, treatment costs for less immunized cases) ratio.